AI424-043-040 An Open-Label Study of the Antiviral Efficacy and Safety of a Novel HIV & Prolease Inhibitor BMS-232632 Versus Lopinavir

Grants and Contracts Details

StatusFinished
Effective start/end date9/26/0111/30/06

Funding

  • Bristol Myers Squibb Company: $13,458.00